Literature DB >> 9860315

Tumor hypoxia and gene expression--implications for malignant progression and therapy.

R M Sutherland1.   

Abstract

Most histopathological classifications of human cancers include significant numbers of hypoxic cells. There is increasing evidence that, at least in certain types of human solid tumors, there is a positive relationship between the presence of hypoxia and poor outcome after radiation therapy alone or radiation combined with other therapies. Hypoxia appears to be an independent prognostic factor. There is evidence for enhanced malignant progression associated with hypoxia, including locoregional invasion and distant metastases. The presence of hypoxia may negatively affect outcome by induction of radiation resistance by the classical oxygen effect and/or by effects on gene expression and malignant progression, causing more aggressive locoregional and distant disease. It is now clear that hypoxia has the potential to influence expression of genes and activities of associated proteins that regulate growth and tissue homeostasis, resulting in cellular phenotypic heterogeneity. The molecular pathways involved in signaling and regulating changes in gene activities in response to external stresses such as hypoxia are becoming known. Identification of patients with hypoxic tumors will lead to improved selective therapy.

Entities:  

Mesh:

Year:  1998        PMID: 9860315     DOI: 10.1080/028418698430278

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  32 in total

1.  Tumoral environment triggers transcript anomalies in established tumors: induction of altered gene expression and of aberrant, truncated and B2 repeat-containing gene transcripts.

Authors:  P Rottiers; M Desmedt; H Dooms; R Contreras; J Grooten
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

2.  Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. Hif-1-independent mechanisms.

Authors:  Z Dong; M A Venkatachalam; J Wang; Y Patel; P Saikumar; G L Semenza; T Force; J Nishiyama
Journal:  J Biol Chem       Date:  2001-03-12       Impact factor: 5.157

Review 3.  Current and future use of positron emission tomography (PET) in breast cancer.

Authors:  David A Mankoff; William B Eubank
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-04       Impact factor: 2.673

4.  Expression of NOS and HIF-1alpha in human colorectal carcinoma and implication in tumor angiogenesis.

Authors:  Jian-Xian Yu; Lin Cui; Qi-Yi Zhang; Hua Chen; Ping Ji; Hong-Jun Wei; Hai-Yan Ma
Journal:  World J Gastroenterol       Date:  2006-08-07       Impact factor: 5.742

Review 5.  Treatment resistance of solid tumors: role of hypoxia and anemia.

Authors:  P Vaupel; O Thews; M Hoeckel
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

Review 6.  Imaging hypoxia in gliomas.

Authors:  I Mendichovszky; A Jackson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

7.  Detection of hypoxia in human brain tumor xenografts using a modified comet assay.

Authors:  Jingli Wang; Jack Klem; Jan B Wyrick; Tomoko Ozawa; Erin Cunningham; Jay Golinveaux; Max J Allen; Kathleen R Lamborn; Dennis F Deen
Journal:  Neoplasia       Date:  2003 Jul-Aug       Impact factor: 5.715

Review 8.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.

Authors:  Randy L Jensen
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

9.  The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy.

Authors:  E Y Tan; M Yan; L Campo; C Han; E Takano; H Turley; I Candiloro; F Pezzella; K C Gatter; E K A Millar; S A O'Toole; C M McNeil; P Crea; D Segara; R L Sutherland; A L Harris; S B Fox
Journal:  Br J Cancer       Date:  2009-01-27       Impact factor: 7.640

10.  BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression.

Authors:  M Yan; M Rayoo; E A Takano; H Thorne; S B Fox
Journal:  Br J Cancer       Date:  2009-09-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.